< Back to search
Filter
1

Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant

for
Myelodysplastic Syndromes
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18 - 70+

Code: NCT04742634

Phase1, Phase2, Recruiting

Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

for
Leukemia, Myelodysplastic Syndromes,
Location: Portland ME, Providence RI, Hartford CT, Lebanon NH,
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 0 - 30

Code: NCT04968834

Recruiting

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

for
Myelodysplastic Syndrome
Location: Boston MA, Lebanon NH, Stony Brook NY, Long Branch NJ,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT06577441

Phase2, Recruiting

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

for
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Location: Boston MA, New Haven CT, Hackensack NJ, Montreal,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT06419634

Phase1, Recruiting

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

for
Acute Lymphoblastic Leukemia,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 18 - 70+

Code: NCT03128034

Phase1, Phase2, Recruiting

Interested in new myelodysplastic syndromes trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

for
Myelodysplastic Syndromes, MDS/MPN Crossover Syndromes
Location: Cleveland OH
Sponsor: Benjamin Tomlinson

Sex: All

Age: 18+

Code: NCT04187703

Early_phase1, Recruiting

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

for
Acute Biphenotypic Leukemia, Acute Myeloid Leukemia,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18 - 65

Code: NCT02115295

Phase2, Recruiting

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

for
Acute Leukemia of Ambiguous Lineage,
Location: Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 0 - 65

Code: NCT06013423

Phase2, Recruiting

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

for
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
Location: Bethesda MD
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Sex: All

Age: 4 - 70+

Code: NCT01174108

Phase2, Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

for
Myelodysplastic Syndromes, Acute Myeloid Leukemia,
Location: St. John's, Boston MA, New Haven CT, Mineola NY,
Sponsor: Taiho Oncology, Inc.

Sex: All

Age: 18+

Code: NCT04256317

Phase2, Phase3, Recruiting

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

for
Acute Leukemia, Acute Lymphoblastic Leukemia,
Location: Pittsburgh PA, Tampa FL, Seattle WA
Sponsor: Fred Hutchinson Cancer Center

Sex: All

Age: 1 - 60

Code: NCT03970096

Phase2, Recruiting

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

for
Childhood Langerhans Cell Histiocytosis, Fanconi Anemia,
Location: Hershey PA
Sponsor: Milton S. Hershey Medical Center

Sex: All

Age: 0 - 21

Code: NCT00084695

Phase2, Recruiting

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

for
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT06543381

Phase1, Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

for
Relapsed/Refractory Acute Myeloid Leukemia (AML),
Location: New York NY, Durham NC, Miami FL, Buffalo NY, Tampa FL,
Sponsor: Cullinan Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT05143996

Phase1, Recruiting

Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome

for
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Location: Rochester NY
Sponsor: University of Rochester

Sex: All

Age: 18+

Code: NCT01311258

Recruiting

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

for
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute,
Location: New York NY, Miami FL, Buffalo NY, Tampa FL,
Sponsor: BlossomHill Therapeutics

Sex: All

Age: 18+

Code: NCT06501196

Phase1, Recruiting

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

for
Acute Leukemia, Acute Myeloid Leukemia,
Location: Philadelphia PA
Sponsor: Children's Hospital of Philadelphia

Sex: All

Age: 0 - 25

Code: NCT03810196

Recruiting

Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

for
Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS
Location: Maywood IL
Sponsor: Patrick Stiff

Sex: All

Age: 2 - 70+

Code: NCT02124174

Phase2, Recruiting

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

for
Clonal Cytopenia of Undetermined Significance,
Location: Los Angeles CA
Sponsor: University of Southern California

Sex: All

Age: 18+

Code: NCT06063486

Phase2, Recruiting

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

for
AML, ALL, Lymphoid Malignancies, Myelodysplastic Syndromes, CML,
Location: Birmingham AL
Sponsor: University of Alabama at Birmingham

Sex: All

Age: 0 - 70+

Code: NCT06047886

Phase1, Recruiting